Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: May 2015

Chapter 17 - Optical coherence tomography in neurologic clinical trials

1.Balcer, LJ, Baier, ML, Cohen, JA, Kooijmans, MF, Sandrock, AW, Nano-Schiavi, ML, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003; 61:13671373.
2.Frohman, EM, Costello, F, Stuve, O, Calabresi, P, Miller, DH, Hickman, SJ, et al. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 2008; 65:2635.
3.Cettomai, D, Pulicken, M, Gordon-Lipkin, E, Salter, A, Frohman, TC, Conger, A, et al. Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol 2008; 65:12181222.
4.Syc, SB, Warner, CV, Hiremath, GS, Farrell, SK, Ratchford, JN, Conger, A, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 2010; 16:829839.
5.Costello, F, Coupland, S, Hodge, W, Lorello, GR, Koroluk, J, Pan, YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59:963969.
6.Ratchford, JN, Saidha, S, Sotirchos, ES, Oh, JA, Seigo, MA, Eckstein, C, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013; 80:4754.
7.Multiple Sclerosis Standards – NINDS Common Data Elements.; 2014.
8.Bermel, RA, Fisher, E, Cohen, JA. The use of MR imaging as an outcome measure in multiple sclerosis clinical trials. Neuroimaging Clin N Am 2008; 18:687701, xi.
9.Warner, CV, Syc, SB, Stankiewicz, AM, Hiremath, G, Farrell, SK, Crainiceanu, CM, et al. The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS One 2011; 6:e22947.
10.Henderson, APD, Altmann, DR, Trip, AS, Kallis, C, Jones, SJ, Schlottmann, PG, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010; 133:25922602.
11.Talman, LS, Bisker, ER, Sackel, DJ, Long, DA,Jr, Galetta, KM, Ratchford, JN, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 2010; 67:749760.
12.Costello, F, Hodge, W, Pan, YI, Eggenberger, E, Freedman, MS. Using retinal architecture to help characterize multiple sclerosis patients. Can J Ophthalmol 2010; 45:520526.
13.Keltner, JL, Cello, KE, Balcer, LJ, Calabresi, PA, Markowitz, CE, Werner, JS. Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials. Neuro-Ophthalmology 2011; 35:5764.
14.Sakai, RE, Feller, DJ, Galetta, KM, Galetta, SL, Balcer, LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol 2011; 31:362373.
15.Winges, KM, Werner, JS, Harvey, DJ, Cello, KE, Durbin, MK, Balcer, LJ, et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American Phase 3 Fingolimod Trial for Relapsing-Remitting Multiple Sclerosis. Journal of Neuro-Ophthalmology 2013; 33: 322329 10.1097/WNO.0b013e31829c51f7.
16.OCTAGON trial. http://clinicaltrials.gov/ct2/show/results/NCT00856635; Accessed 12/2013.
17.Suhs, KW, Hein, K, Sattler, MB, Gorlitz, A, Ciupka, C, Scholz, K, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72:199210.
18.Treatment of Optic Neuritis With Erythropoietin (TONE). http://clinicaltrials.gov/ct2/show/results/NCT00856635; Accessed 01/2014.
19.Esfahani, MR, Harandi, ZA, Movasat, M, Nikdel, M, Adelpour, M, Momeni, A, et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol 2012; 250:863869.
20.Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis. http://clinicaltrials.gov/show/NCT01982942; Accessed 12/2013.
21.MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial. http://clinicaltrials.gov/show/NCT01910259; Accessed 01/2014.
22.Neuroprotection with phenytoin in optic neuritis. http://clinicaltrials.gov/show/NCT01451593; Accessed 12/2013.
23.Amiloride clinical trial in optic neuritis. http://www.clinicaltrials.gov/show/NCT01802489; Accessed 12/2013.
24.Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON). http://www.clinicaltrials.gov/show/NCT01802489; Accessed 01/2014.
25.215ON201 BIIB033 In Acute Optic Neuritis (AON) (RENEW). http://clinicaltrials.gov/show/NCT01721161; Accessed 01/2014.
26.Connick, P, Kolappan, M, Crawley, C, Webber, DJ, Patani, R, Michell, AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11:150156.
27.Waubant, E. A phase II trial of neuroprotection with riluzole in early relapsing-remitting MS. ECTRIMS 2013, Copenhagen, Denmark. Late Breaking News Session 10/05/2013.